皮下英夫利西单抗治疗肛周克罗恩病:GETAID多中心研究
该多中心回顾性队列研究纳入183例肛周克罗恩病患者,评估皮下英夫利西单抗的疗效与安全性。活动期组6个月临床缓解率44.6%、应答率87.7%;非活动期组6和12个月无复发生存率分别为94.3%和87.9%,仅8.3%出现注射相关不良事件。
要点
- 活动期肛周CD换用皮下IFX后6个月临床缓解率44.6%、应答率87.7%
- 非活动期患者从静脉换皮下后6和12个月无复发生存率94.3%和87.9%
- 高BMI是活动期患者6个月缓解的唯一独立负性预测因素(OR 0.88)
核心结论
- 皮下英夫利西单抗对活动性肛周克罗恩病有效且安全,换药后维持缓解亦有效,支持常规实践应用。
研究设计与样本
- GETAID开展的多中心回顾性队列研究,共纳入24个中心183例患者,活动期组66例、非活动期组117例。
主要发现
- 活动期组6个月临床缓解率44.6%,临床应答率87.7%,含取除挂线的临床缓解率35.5%。
- 非活动期组6个月和12个月无复发生存率分别为94.3%和87.9%。
- 多变量分析中高BMI是活动期组缓解的唯一独立预测因素(OR 0.88,95%CI 0.77-0.99)。
临床怎么用
- 活动性肛周克罗恩病可考虑使用皮下英夫利西单抗诱导缓解。
- 静脉英夫利西单抗治疗后换用皮下制剂可有效维持缓解。
- 高BMI患者皮下英夫利西单抗缓解率可能较低,需关注。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Intravenous infliximab (IFX) is the cornerstone for treating patients with perianal Crohn's disease (pCD). Data on the recently launched subcutaneous (SC) IFX for pCD are limited. The aim of our study was to evaluate the effectiveness and safety of SC IFX in pCD. METHODS: We conducted a multicenter retrospective cohort study from the GETAID, including patients with either active (group 1) or inactive (group 2) pCD when they started SC IFX. Inclusion criteria were, for group 1: active pCD in the 6 months before initiation of SC IFX; for group 2: inactive pCD for >6 months at the time of IV to SC switch. The primary end points were clinical remission at 6 months in group 1 and pCD relapse in group 2. RESULTS: Of the 183 patients included in 24 centers, 66 were in group 1 and 117 in group 2. The median follow-up was 50.4 (27.0-64.6) and 53.4 (40.6-67) weeks, respectively. In group 1 at 6 months, clinical remission was observed in 44.6% of patients and clinical response in 87.7%. Clinical remission including seton removal occurred in 35.5% of patients. In multivariable analysis, high body mass index was the only independent predictor of remission (odds ratio 0.88, 95% confidence interval 0.77-0.99). In group 2, rates of relapse-free survival were 94.3% and 87.9% at 6 and 12 months, respectively. Sixteen cases (8.3%) of adverse events related to SC injection were observed. DISCUSSION: SC IFX was effective and safe for the treatment of active pCD and for maintaining remission after switching in this large multicenter cohort, thus supporting its use in routine practice in this indication.
引用
- André M, Kirchgesner J, Laharie D, et al. Subcutaneous Infliximab for Perianal Crohn's Disease: The BioLap-Rem Multicenter Study From the GETAID. Am J Gastroenterol. 2025. PMID: 40874971. doi:10.14309/ajg.0000000000003755
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。